Korro Bio (NASDAQ:KRRO) Posts Earnings Results, Misses Estimates By $0.04 EPS

Korro Bio (NASDAQ:KRRO) announced its earnings results on Tuesday. The company reported ($2.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.39) by ($0.04), Yahoo Finance reports.

Korro Bio Stock Up 5.0 %

Shares of KRRO stock traded up $1.80 on Wednesday, hitting $38.16. 15,489 shares of the stock traded hands, compared to its average volume of 49,927. Korro Bio has a 52 week low of $9.15 and a 52 week high of $97.91. The firm has a 50 day simple moving average of $41.30 and a two-hundred day simple moving average of $53.21.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on KRRO shares. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Korro Bio in a research report on Wednesday. William Blair began coverage on Korro Bio in a research report on Wednesday. They set an “outperform” rating and a $180.00 target price on the stock. Finally, BMO Capital Markets restated an “outperform” rating and issued a $120.00 price target on shares of Korro Bio in a research report on Wednesday, May 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $134.00.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).